Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy

作者：Jogamoto Toshihiro; Yamamoto Yoshiaki; Fukuda Mitsumasa^*; Suzuki Yuka; Imai Katsumi; Takahashi Yukitoshi; Inoue Yushi; Ohtsuka Yoko

来源：Epilepsy Research, 2017, 130: 7-12.

DOI：10.1016/j.eplepsyres.2016.12.014

• CYP2C19
• Dravet syndrome
• Stiripentol
• Topiramate
• Valproate

Objective: Stiripentol (STP), valproate (VPA) and topiramate (TPM) are reported to have efficacy for Dravet syndrome. In this study, we sought to elucidate the mechanisms underlying the increased serum VPA concentrations following STP adjunctive therapy in patients with Dravet syndrome.
Methods: Twenty-eight patients with Dravet syndrome (age range, 1-35 years) undergoing combination therapy with VPA and STP were included in this study. We evaluated VPA and clobazam (CLB) serum concentrations before and after add-on STP. We also investigated potential factors impacting VPA metabolism during add-on STP therapy, including add-on TPM and CYP2C9 and CYP2C19 gene polymorphisms. The effect of STP on the metabolism of concomitantly administered CLB was also investigated.
Results: Add-on STP was significantly associated with the serum concentration-to-dose(CD) ratio of VPA. Two patients, who were concomitantly treated with TPM, developed severe anorexia and thrombocytopenia because of marked increases in serum VPA concentrations. Further analysis revealed that the rate of increase in the VPA CD ratio was positively correlated with TPM dose. In patients not receiving TPM, STP enhanced the rate of increase in the VPA CD ratio to a significantly greater extent in CYP2C19 extensive metabolizers than in CYP2C19 poor metabolizers. Add-on STP was also associated with significant increases in CLB and N-desmethyl-CLB serum concentrations.
Conclusion: Our findings suggest that serum VPA concentrations should be carefully monitored during STP adjunctive therapy, particularly in patients receiving concomitant TPM therapy.

• 出版日期2017-2